Form 4 for CRSP CRISPR Therapeutics AG
Accepted 2021-12-22 00:00:00 ET · period of report 2021-12-20 · accession 0001209191-21-070994 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-12-22 | 2021-12-20 | CRSP | Kulkarni Samarth | CEO, Dir | M - OptEx | $1.81 | +17.8K | 279.1K | +7% | +$32.1K |
| D | 2021-12-22 | 2021-12-20 | CRSP | Kulkarni Samarth | CEO, Dir | M - OptEx | $0.00 | -17.8K | 58.2K | -23% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2021-12-20 | M | A | 17,750 | $1.81 | 279,085 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2021-12-20 | M | D | 17,750 | $0.00 | 58,233 | D | $1.81 · — to 2025-09-10 | 17,750 Common Shares | (F1) This option was granted on September 10, 2015 with respect to 321,712 Common Shares with 120,640 of the shares vested on August 1, 2016, the first anniversary of employment commencement, and the remainder vested in equal 36 monthly installments thereafter. |